Clinical trials: Hematopoietic Stem Cell Mobilization
Children Cancer, Solid Tumor
Mobilization by Plerixafor of Haematopoietic Stem Cells in Children
This is a prospective Phase II, monocentre study.
- Trial name
- MEP1 (NCT01225419)
- Testing
- Plerixafor, mozobil
- Where
- France
- Volunteers
- 5 people
- Sponsor
- University Hospital, Clermont-Ferrand
Multiple Myeloma
Chemotherapy and G-CSF for Mobilization
This study aims to demonstrate that the mobilization with cytokine stimulation with G-CSF alone is non-inferior as compared to the standard mobilization with chemotherapy and G-CSF while associated with fewer side effects in…
- Trial name
- MOCCCA (NCT03442673)
- Testing
- Vinorelbine, Gemcitabine, G-CSF
- Where
- Switzerland
- Volunteers
- 137 people
- Sponsor
- Insel Gruppe AG, University Hospital Bern
Coronary Arteriosclerosis
The Effect of Exercise on Stem Cell Mobilization and Heart Function in Patients Undergoing Cardiac Rehabilitation
This study will look at the effect of a cardiac rehabilitation exercise program on release of stem cells from the bone marrow and on heart function.
- Trial name
- NCT00053456
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Severe Combined Immunodeficiency
Hematopoietic Stem Cell Transplantation (HSCT) for Children With SCID Utilizing Alemtuzumab, Plerixafor & Filgrastim
The goal of this study is to develop a novel approach to hematopoietic stem cell transplantation for children with Severe Combined Immunodeficiency Disease (SCID) that eliminates the use of toxic chemotherapy conditioning and…
- Trial name
- NCT01182675
- Testing
- Transplant Conditioning with Mobilization Only, Transplant Conditioning with Mobilization and Alemtuzumab
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- University of California, San Francisco
Solid Malignancies
Evaluation of Pegfilgrastim for Stem Cell Mobilization in Children
Hypothesis: pegfilgrastim at 300 µg/kg in hematological steady state provides an efficient stem cell mobilization in children with malignancies Design: phase 2 study.
- Trial name
- NCT00695370
- Testing
- Pegfilgrastim (drug)
- Volunteers
- 30 people
- Sponsor
- University Hospital, Clermont-Ferrand
Beta-Thalassemia
Evaluating the Safety and Effectiveness of Mozobil Mobilization in Adults With Beta-Thalassemia Major
Thalassemia is considered the most common genetic disorder worldwide, occurring with high frequency in Mediterranean areas, the Middle East, Southeast Asia, and the Pacific Islands.
- Trial name
- NCT01206075
- Testing
- Mozobil
- Where
- Greece
- Volunteers
- 20 people
- Sponsor
- University of Washington
Peripheral Blood Stem Cell Transplantation
KRN125 for Mobilization of Hematopoietic Stem Cells
Data collection to evaluate safety and effect of hematopoietic stem cell mobilization into the peripheral blood after a single subcutaneous (SC) dose of KRN125(Pegfilgrastim)in healthy adults.
- Trial name
- NCT03993639
- Testing
- Pegfilgrastim
- Where
- Japan
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- Kyowa Kirin Co., Ltd.
Hematologic Neoplasms
National Marrow Donor Program Long-Term Donor Follow-Up
This is an observational study of unstimulated bone marrow (BM) and filgrastim-mobilized peripheral blood stem cell (PBSC) donors.
- Trial name
- LTDFU (NCT01362179)
- Where
- 29 sites in United States, Puerto Rico
- Volunteers
- 21,974 people
- Sponsor
- Center for International Blood and Marrow Transplant Research
Autologous Stem Cell Transplant
Access Program for Use of AMD3100 to Increase Peripheral Blood Stem Cells for Transplantation in Patients Who Have Failed Standard Therapy Stem Cell Mobilization
The purpose of this program is to provide access to AMD3100 for patients who would benefit from an autologous stem cell transplant but who have either previously failed to collect enough cells for transplant following standard…
- Trial name
- CUP (NCT00291811)
- Testing
- AMD3100 + G-CSF
- Sponsor
- Genzyme, a Sanofi Company
Myocardial Infarction
Stem Cell Mobilization by G-CSF Post Myocardial Infarction to Promote Myocyte Repair
Eighty-six patients with heart attacks will be identified at our hospital. Post heart attack we will assess heart function, blood flow to the heart, and heart cell function.
- Trial name
- NCT00394498
- Testing
- Granulocyte Colony Stimulating Factor
- Where
- Canada
- Volunteers
- 86 people
- Sponsor
- University of Ottawa
Multiple Myeloma
First Line Treatment Trial in Multiple Myeloma, Finnish Myeloma Group- Multiple Myeloma 02
The purpose of this study is to determinate the efficacy and safety of the 3-drug induction treatment (RVD; lenalidomide plus bortezomib plus dexamethasone)followed by randomized autologous stem cell mobilization, autologous stem…
- Trial name
- FMG-MM02 (NCT01790737)
- Testing
- Cyclophosphamide, Filgrastim
- Where
- 12 sites in Finland
- Volunteers
- 80 people
- Sponsor
- Kuopio University Hospital
Diamond Blackfan Anemia
Mobilization of Stem Cells With G-CSF for Collection From Patients With Diamond-Blackfan Anemia
This study will provide information needed to develop more effective treatments for patients with Diamond-Blackfan anemia (DBA). Current treatments include steroids, such as prednisone, and blood transfusions.
- Trial name
- NCT00011505
- Testing
- G-CSF, Leukapheresis
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Multiple Myeloma
Randomized Trial of G-CSF Alone Versus Intermediate-dose Ara-C Plus G-CSF Mobilization in Multiple Myeloma Patients.
The purpose of the study is to compare safety and efficacy of stem cell mobilization using G-CSF (filgrastim) alone vs. intermediate-dose cytosine arabinoside plus G-CSF in multiple myeloma patients.
- Trial name
- NCT01908621
- Testing
- G-CSF (filgrastim), Cytosine arabinoside + G-CSF (filgrastim)
- Where
- Poland
- Volunteers
- 90 people
- Sponsor
- Maria Sklodowska-Curie National Research Institute of Oncology
Stem Cell Transplant Complications
Loratadine for the Prevention of G-CSF-related Bone Pain
The research question for the current study is: Is loratadine more effective than placebo in preventing G-CSF-related bone pain during autologous hematopoetic stem cell transplant in patients with lymphoma or multiple myeloma?…
- Trial name
- NCT05421416
- Testing
- Loratadine
- Where
- Canada
- Volunteers
- 78 people
- Sponsor
- AHS Cancer Control Alberta
Stem Cell Transplantation, Hematopoietic, Poor Graft Function
Peripheral Blood Stem Cell Combined With Mesenchymal Stem Cells for Treatment of Poor Graft Function
The purpose of this study is to evaluate the utility of treating patients experiencing poor graft function after allogeneic hematopoietic stem cell transplantation with Granulocyte Colony-Stimulating Factor (G-CSF) mobilized…
- Conditions
- Stem Cell Transplantation, Hematopoietic, Poor Graft Function, Hematological Diseases
- Trial name
- NCT02083718
- Testing
- PBSC, MSCs
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission
Plerixafor and Filgrastim For Mobilization of Donor Peripheral Blood Stem Cells Before A Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies
RATIONALE: Giving chemotherapy and total-body irradiation (TBI) before a donor peripheral blood stem cell transplant helps stop the growth of cancer cells and helps stop the patient's immune system from rejecting the donor's stem…
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
- Trial name
- NCT01076270
- Testing
- plerixafor, filgrastim, peripheral blood stem cell transplantation
- Where
- United States
- Volunteers
- 1 people, healthy volunteers welcome
- Sponsor
- Fred Hutchinson Cancer Center
Healthy
AMD 3100 (Mozobil Plerixafor) to Mobilize Stem Cells for Donation
Peripheral blood progenitor cells (PBPC) have become the preferred source of hematopoetic stem cells for allogeneic transplantation because of technical ease of collection and shorter time required for engraftment.
- Trial name
- NCT00075335
- Testing
- AMD3100 (Mozobil plerixafor)
- Where
- United States
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Chronic Myeloid Leukemia, Myelodysplastic Syndrome
Expanded Use of G-CSF Mobilized Donor CD34+ Selected Cells for Allogeneic Transplantation
Allogeneic hematopoietic stem cell transplantation (HSCT) is an established form of treatment for hematological abnormalities. Poor graft function, occurs when there poor donor engraftment.
- Conditions
- Chronic Myeloid Leukemia, Myelodysplastic Syndrome, Acute Myeloid Leukemia
- Trial name
- NCT02258490
- Testing
- G-CSF mobilized CD34+ selected cells for transplantation
- Where
- United States
- Sponsor
- Emory University
Leukapheresis
Evaluation of the Spectra Optia® Apheresis System Mononuclear Cell (MNC) Collection Procedure in Healthy Blood Donors
The purpose of this protocol is to characterize the performance of CaridianBCT's Spectra Optia Apheresis System, when used to collect mononuclear cells (MNCs) and cluster of differentiation 34 (CD34) positive cells from healthy…
- Trial name
- NCT01277549
- Testing
- Mononuclear cell collection.
- Where
- 3 sites in United States
- Volunteers
- 71 people, healthy volunteers welcome
- Sponsor
- Terumo BCT
Multiple Myeloma
Trial of Three Stem Cell Mobilization Regimens for Multiple Myeloma
This phase III randomized trial compares three different peripheral stem cell mobilization regimens for patients with multiple myeloma who have received primary induction therapy or other therapies.
- Trial name
- NCT01146834
- Testing
- bortezomib (Velcade), cyclophosphamide, G-CSF
- Where
- 5 sites in United States
- Volunteers
- 47 people
- Sponsor
- Weill Medical College of Cornell University